Complix to Present at Upcoming BioEquity Europe 2013: http://t.co/jzPUX0k7Bp
FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.
Ablynx [Euronext Brussels: ABLX] announced today detailed results from the open label extension of the Phase Ib study of its anti-thrombotic, ALX-0081, in patients with stable angina undergoing percutaneous coronary intervention (PCI). read more
Movetis announces today that Credit Suisse and KBC Securities, acting as Joint Global Coordinators and on behalf of the bank syndicate, have fully exercised the Over-allotment Option, in accordance with provisions contained in the initial public offering (IPO) prospectus. read more
ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that it has completed the enrolment of the second Phase III trial evaluating microplasmin for the non-surgical treatment of eye disease. read more